Side-by-side · Research reference
PEG-MGFvsTB-500
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED2/69 cited
BPhase 2HUMAN-REVIEWED8/46 cited
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
01Mechanism of Action
Parameter
PEG-MGF
TB-500
Primary target
IGF-1 receptor on muscle satellite cells and myocytes
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
Partially bypassed — does not require hepatic IGF-1 synthesis
Endogenous protein at baseline; supplementation amplifies
Origin
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
Unknown — no long-term human immunogenicity data
—
02Dosage Protocols
Parameter
PEG-MGF
TB-500
Research dose range
100–200 mcg
Extrapolated from animal models; no validated human protocols.
—
Frequency
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
2× per week (loading); then 1× per week (maintenance)
Half-life
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
~2 hours (estimated; tissue uptake longer)
Reconstitution
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Bacteriostatic water, 1–2 mL per 5 mg vial
PEG molecular weight
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
—
Timing
Within 30–60 min post-training
Aligns with endogenous MGF window.
Evening or pre-rest preferred (anecdotal)
Standard dose
—
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Lower / starter dose
—
1 mg per injection
Duration
—
4–8 weeks loading; longer maintenance for chronic injury
03Metabolic / Fat Loss Evidence
Parameter
PEG-MGF
TB-500
Primary target
Muscle tissue (satellite cells, myocytes) — not adipose-specific
—
Indirect metabolic effect
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
—
Body composition
Lean mass preservation / hypertrophy focus
—
Fat loss evidence
No direct human or animal RCT data for PEG-MGF-driven fat reduction
—
04Side Effects & Safety
Parameter
PEG-MGF
TB-500
Injection site reaction
Erythema, induration (common with SQ peptides)
Mild erythema, transient pain
Hypoglycemia risk
IGF-1 axis activation can lower blood glucose
—
IGF-1R overstimulation
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
—
Fluid retention
Possible with IGF-1 pathway activation (dose-dependent)
—
PEG accumulation
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
—
Antibody formation
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
No data (no long-term human trials)
Cancer risk
IGF-1 axis stimulation contraindicated in active malignancy
Theoretical via angiogenesis pathway
Human safety data
Absent — no published human trials for PEG-MGF
—
GI symptoms
—
Rare nausea (anecdotal)
Lethargy / fatigue
—
Reported anecdotally during loading phase
Pregnancy / OB
—
Avoid
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Relative Contraindications
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
05Administration Protocol
Parameter
PEG-MGF
TB-500
1. Reconstitution
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair